The CMS is proposing a new rule to control skin substitute spending by capping payment rates, eliminating separate selling prices, and reducing reimbursement in physician offices. Northland analyst Carl Byrnes sees this as a positive for MiMedx, maintaining a Buy rating with a $12 price target. The stock is down 11% in premarket trading.

Read more at Yahoo Finance: Northland sees ‘key positive’ for MiMedx in CMS rule proposal